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Background. FDG-PET scan detects extrahepatic metastases in 20% of patients with colorectal liver metastases but it is reported to
have approximately 16% false negative rates. Patients and Methods. Patients who had PET scan for metastatic colorectal cancer at
Westmead Hospital between March 2006 and March 2010 were reviewed retrospectively. The results of PET scan were correlated
withtumourcharacteristicsthatwerethoughttoaﬀecttheoverallprognosis.Results.Degreeoftumourdiﬀerentiationandvascular
invasion were signiﬁcantly predictive for the presence of extrahepatic disease on PET scan, also did the level of CEA. Conclusion.
The detection of extrahepatic disease in colorectal liver metastases correlates with the biologic behaviour of the primary tumour.
Poorly diﬀerentiated tumours and those with lymphovascular invasion behave in aggressive fashion and likely to have wide-spread
metastases. This should be considered when contemplating liver resection for colorectal metastases.
1.Introduction
Liver resection is currently the most eﬀective treatment
for patients with colorectal cancers metastatic to the liver.
Stringent selection policy is necessary because there is no
survival beneﬁt if residual disease is left elsewhere after
hepatectomy [1].
FDG-PET scan detects extrahepatic metastases in 20%
of patients with colorectal liver metastases but it is reported
to have approximately 16% false negative rates [2]. Positron
emission tomography with the glucose analog [18F] ﬂuoro-
2-deoxy-D-glucose is a sensitive diagnostic test that detects
tumours based on the increased metabolic utilisation of
glucose by tumour cells. FDG-PET has been demonstrated
to be more sensitive than CT in the detection of metastatic
colorectaladenocarcinoma,particularlyinextrahepaticloca-
tions [3].
Positron emission tomography provides useful informa-
tion in the selection of patients with hepatic metastases from
colorectal cancer being considered for surgical therapy; it
alters the decision of management in 15% of such patients,
which helps to reduce the number of unnecessary surgical
explorations and results indirectly in improved survival in
patients undergoing hepatic resection [4]. Positron emission
tomography is currently being routinely integrated in pre-
operative evaluation of patients being considered for liver
resection of colorectal metastases.
Theoverallsensitivityof97%andanoverallspeciﬁcityof
76% for FDG-PET in detecting recurrent colorectal cancer
were documented by one systematic review and meta-
analysis of studies conducted to investigate the role of PET
in colorectal liver metastases [5].
Fernandez et al. reviewed the literature for ﬁve-year
survival after liver resection for colorectal metastases before
the introduction of PET scan used to be average of 30% (12–
40%). With the routine use of PET scan the actuarial ﬁve-
years survival has improved to up to 58% [3].
Previous studies found some correlation between certain
clinicalindicatorssuchasintervalforhepaticrecurrence,size
oflivermetastases,andCEAlevelsandtheresultsofPETscan
for detection of extrahepatic metastases [2].
T u m o u rb i o l o g ya sr e ﬂ e c t e db yd e g r e eo fd i ﬀerentiation,
nodal metastases, T stage, and possibly other biologic
markers is found to aﬀect the overall survival after liver
resection for metastatic colorectal cancer [6].2 ISRN Oncology
We designed this study to estimate the correlation
between clinical factors related to the diseases and patholog-
ical features of the primary colorectal cancer with the results
of PET scan for patients presented with liver metastases and
being considered for liver resection.
2. Patientsand Methods
The database for PET scan records was searched for patients
who had PET scan with history of colorectal cancer and their
imaging showed hepatic metastases. Patients were identiﬁed
and their medical records were reviewed. Patients who
proved to have liver metastases on PET scan were included
in this study for the period between March 2006 and March
2010.
Data collected include demographics and interval
between colorectal cancer resection and the appearance of
liver metastases; results of the PET scan were recorded and
included presence of extrahepatic disease, number and size
of liver metastases, and bilobar liver disease; conventional
cross-sectionalimagingdatawererecorded.Wealsocollected
data from operative reports (including the ﬁndings on
intraoperative ultrasound) and perioperative records.
The pathology report of the primary colorectal cancer
wasreviewed,anddataextractedincludedsiteoftheprimary
disease, degree of diﬀerentiation, lymphovascular invasion,
T stage, N stage, and apical nodes involvement. Factors
thoughttocorrelatewiththepresenceofextrahepaticdisease
were analysed using chi-squared test. Multivariate analysis
was performed using logistic regression test for independent
factors that correlate with extrahepatic disease detection as
found on PET scan.
3. Results
Between 2006 and March 2010, 230 PET scans were per-
formed; 174 patients with history or newly diagnosed with
colorectal cancer had PET scan for evaluation of suspected
liver metastases; the rest of the patients either had rising
CEA or suspected extrahepatic metastases. These patients
had suspicious liver lesions on CT scan and/or rising CEA
levels. 106 patients (47 women and 59 men) with median age
of 63 (range 26–88) proved to have liver metastases with or
without extrahepatic recurrence.
The site of primary lesion was in the right colon in 25
patients, rectum in 20 patients, left colon and sigmoid in 56
patients, and transverse colon in 5 patients. All patients had
CT scan of the chest, abdomen, and pelvis.
Liver metastases were synchronous in 30 patients, 37
patients had recurrence within 12 months of resection of
the colorectal cancer, and 39 patients had recurrence after
12 months (range 14–72 months). PET scan was false-
negative in three patients who had CT evidence of liver
disease and proceeded to have liver resection, which proved
the metastatic nature of the lesion that was seen on cross-
sectional imaging. PET scan detected lesions that were
n o ts e e no nC Ts c a ni n1 2p a t i e n t s ,e i g h to ft h o s ew e r e
extrahepatic lesions and four were liver lesions.
Pathology of the primary colorectal cancer was moder-
ately diﬀerentiated in 72 patients (68%), poorly diﬀerenti-
atedin30patients(28%),andwelldiﬀerentiatedin4patients
(4%). Lymphovascular invasion was absent in 70 patients
(66%)andwasseenin36patients(34%).Theprimarylesion
wasT2in14patients,T3in72patients,andT4in20patients.
The disease was N0 in 23 patients and N2 in 83 patients.
Apical lymph nodes were involved in 11 patients.
There was one liver lesion in 47 patients, 19 patients had
twolesions,9patientshadthreelesions,8patientshad4liver
lesions, and 23 patients had ﬁve or more lesions. The disease
was bilobar in 27 patients.
CEA level was normal in 18 patients, and serum levels
ranged between 0.5mcg/L and 16223mcg/L.
PET scan showed that the disease was limited to the
liver in 65 patients and 41 patients had extrahepatic disease.
The most frequent sites were lungs, peritoneal disease, local
recurrence, mediastinal nodes, and occasionally bones and
brain.
3.1. Statistical Analysis. Data were analysed using StatsDi-
rect.Univariateanalysisoffactorsthatmaycorrelatewiththe
presence of extrahepatic disease showed that lymphovascular
invasion, degree of diﬀerentiation, T stage, CEA level, size of
metastases, and bilobar disease were signiﬁcant predictors of
the presence of extrahepatic disease (see Table 1).
Multivariateanalysiswasperformedusingstepwiselogis-
tic regression test showing that vascular invasion, degree
of diﬀerentiation, and CEA level are the only independent
factors that predict the presence of extrahepatic disease (see
Table 2).
4. Discussion
Cross-sectional radiologic imaging utilizing abdominal and
pelvic CT scan is the most commonly used imaging to evalu-
ate liver anatomy and assess for the presence of extrahepatic
disease in patients with colorectal liver metastases who are
potential candidates for curative liver resection.
PET scan was found in other studies to reduce the
rate of nontherapeutic laparotomy from 15% to less than
5% [7]. The same investigators from John Hopkins Center
tumor number greater than ﬁve, bilateral liver disease
and tumor size larger than 5cm were independent factors
associated with presence of extrahepatic disease. Huebner
et al. conducted a meta-analysis of 11 articles of the use of
PET scan for colorectal liver metastases; they determined, an
overall sensitivity of 97% (95% conﬁdence level: 95–99%)
and an overall speciﬁcity of 76% (95% conﬁdence level, 64–
88%) for FDG PET detecting recurrent CRC throughout the
whole body. Furthermore, through pooling of the change-
in-management data, an overall FDG PET-directed change
in management was calculated to be 29% (95% conﬁdence
level: 25–34%) [5].
The present study is a retrospective review of patients
referred to Westmead Hospital for assessment of colorectal
liver metastases to conﬁrm the extent of liver disease and to
assess for the presence or absence of extrahepatic disease;ISRN Oncology 3











Less than 60 years 17 23 .6
Over 60 years 24 42
Interval for recurrence
Less than 12 months 31 37 .08
More than 12 months 10 28
Degree of diﬀerentiation
of primary tumour
Well moderate 59 18 <.0001
Poor 6 23
Lymphovascular invasion
Present 61 9 <.0001
Absent 4 32
Ts t a g e
T2 12 2 .02
T3-4 53 39
Ns t a g e
N0 16 7 .4
N1 49 34
CEA level
Less than 20mcg/L 41 12 .001
More than 20mcg/L 24 27
Size of the liver metastases
Less than 5cm 47 21 .02
5cmormore 18 20
Bilobar Disease
.001 Yes 7 21
No 58 20
due to the pattern of referral we were able to review only
patientswhohadtheirmedicalrecordatWestmeadHospital.
The subjects of this study were patients who proved to
have liver metastases on cross-sectional imaging and PET
scan. We correlated clinical factors and pathology of the
primary colorectal cancer with the ﬁnding of the PET scan.
On multivariate analysis we found that presence of vascular
invasion, degree of diﬀerentiation of the primary lesion, and
CEA level are the only factors associated with the presence
or absence of extrahepatic disease. While tumour stage of
the primary and nodal metastases, time interval between the
diagnosis of the primary and the recurrence, and size and
number of metastases in the liver were signiﬁcant predictors
on univariate analysis; they were not signiﬁcant factors in
the multivariate analysis. Lymphovascular invasion seems to
be a very signiﬁcant factor in tumour biology; patients with
primary tumor showing lymphovascular invasion would
have a signiﬁcant higher chance of lymph node metastasis.
Positive lymph node status was predictive of poorer survival
Table 2
diﬀ P = .0046
vascular P<. 0001
T P = .8301
Size P = .3677
Bilobar P = .3571
CEA P = .024
Logistic regression-odds ratios
Parameter Odds ratio 95 CI
diﬀ 11.536075 2.12326 to 62.67768
vascular 41.720557 8.388554 to 207.497598
T 1.145417 0.331347 to 3.959542
Size 0.472701 0.092598 to 2.413074
Bilobar 2.327326 0.385553 to 14.048527
CEA 6.23202 1.5 to 3.7
inpatientswithT1orT2colorectalcancers.Forthosecancers
with positive lymphovascular permeation, radical surgery is
recommended [8].
Lim et al. studied 2417 patients; a lymphovascular
invasion-positive tumor was detected in (25.2%). Com-
pared with patients with lymphovascular invasion-negative
tumors,thosewithlymphovascularinvasion-positivetumors
had higher preoperative serum carcinoembryonic antigen
levels. Their tumors were also more likely to be poorly
diﬀerentiated and more advanced in terms of T and N
categories. The lymphovascular invasion-positive tumors
were also more likely to have metastasized systemically.
Lymphovascular invasion-positive tumors metastasized to
systemic lymph nodes more often. These tumors also
recurred at systemic lymph nodes after curative intent
surgerymoreoften.Lymphovascularinvasion-positive status
was an independent unfavorable prognostic factor for the 5-
year overall and 5-year disease-free survival of patients with
sporadic colorectal cancer [9].
Pawlik et al. described factors associated with nonther-
apeutic laparotomy for colorectal liver metastases, which
included size of metastases, number of metastases, and bilat-
eral disease [7]; however, they did not include factors related
totheprimarycancerpathology.Inclusionoftumour-related
factors in our study has shown that liver lesion factors
are important determinants on their own but were not
signiﬁcant in multivariate analysis. Disease-free interval was
shown in some previous studies to be an important factor
that predicts extrahepatic disease [2]. In our study and the
study by Pawlik et al. [7], time interval was not a signiﬁcant
factor in prediction of behaviour of colorectal cancer spread.
It has been described that overall survival for patients
undergoing curative resection for colorectal liver metastases
can be predicted from the pathologic features of the primary
colorectal cancer [6] depending on the degree of diﬀerentia-
tion of the primary cancer and presence or absence of lymph
nodes metastases. Survival after resection of colorectal liver
metastases is continually improving due to better patients’
selection, improved postoperative care, and more eﬀective
chemotherapy agents [10].4 ISRN Oncology
Das et al. have investigated the signiﬁcance of pathologic
and biology features of primary rectal cancer and concluded
that pathologic T and N stages signiﬁcantly predicted overall
survival, distant metastases, and loco regional recurrence
on multivariate analysis and that indirectly is an indication
for investigations of more aggressive adjuvant chemother-
apy for locally advanced rectal. More recent aggressive
chemotherapy and molecular therapy had shown signiﬁcant
improvement of overall survival for metastatic colorectal
cancer [11, 12]. In another study, Harris et al. investigated
factors that aﬀect survival in patients present with advanced
metastatic colorectal cancer and, on multivariate analysis,
factors that had impact on survival included, T stage, N
stage, and degree of diﬀerentiation of the primary disease
[13]. In patients with locally advanced rectal cancer who
underwent total mesorectal excision the independent factors
for poor survival were the advanced stage of the disease
and the presence of lymphovascular and perineural invasion
[14]. In patients with Duke’s B stage the presence of
lymphovascular invasion is associated with increase rate of
disease recurrence, and hence this feature is used as an
indicationforchemotherapyaftercurativeresection[15,16].
Biology of the primary tumor is increasingly being
recognized as a primary determinant factor in disease
behavior and overall outcome; one such factor is perineural
invasion (PNI): in one study it was detected in 57 of 341
patients (16.7%) and was signiﬁcantly associated with depth
of tumor invasion and positive lymphovascular invasion.
Multivariate analyses revealed that PNI was a signiﬁcant
independent prognostic factor for disease-free survival, not
for overall survival [17]. More emphasis on the biology of
the primary tumor has been focused on the genetic features
of the primary tumor in one study of primary colorectal
cancer; p53 mutations were a signiﬁcant negative prognostic
indicator for overall survival. This ﬁnding holds prognostic
andtherapeuticimplicationsforthemanagementofcolorec-
tal carcinoma patients [18, 19]. Future investigations may
reveal more molecular markers that not only may predict
prognosis butalsowillhaveimplications ofinvestigation and
treatment of metastatic disease, which may dictate which
subset of patients with liver metastases should undergo PET
scan imaging.
Biology of liver metastases tends to follow the features of
the primary disease. Rajaganeshan et al. studied this subject
and found that primary cancers with a high microvaswcular
density (MVD) tended to form high MVD liver metastases.
Microvessel density was a signiﬁcant predictor of disease
recurrence in Primary tumour tumours. These results sug-
gest that primary CRCs and their liver metastases show
common histological features [20]. And those tumours with
high microvascular density have high risk for recurrence
[21].
In conclusion, biological factors related to the primary
tumours such as vascular invasion, degree of diﬀerentiation,
p53 mutation, microvascular density, and perhaps new
molecular agents may be useful in the future to guide the
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